Logo image of DYN

DYNE THERAPEUTICS INC (DYN) Stock Fundamental Analysis

NASDAQ:DYN - Nasdaq - US26818M1080 - Common Stock - Currency: USD

9.01  +0.37 (+4.28%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to DYN. DYN was compared to 558 industry peers in the Biotechnology industry. While DYN has a great health rating, there are worries on its profitability. DYN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DYN has reported negative net income.
DYN had a negative operating cash flow in the past year.
DYN had negative earnings in each of the past 5 years.
DYN had a negative operating cash flow in each of the past 5 years.
DYN Yearly Net Income VS EBIT VS OCF VS FCFDYN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

DYN has a Return On Assets (-50.91%) which is comparable to the rest of the industry.
DYN's Return On Equity of -54.88% is fine compared to the rest of the industry. DYN outperforms 62.90% of its industry peers.
Industry RankSector Rank
ROA -50.91%
ROE -54.88%
ROIC N/A
ROA(3y)-81.24%
ROA(5y)-59.12%
ROE(3y)-125.15%
ROE(5y)-86.67%
ROIC(3y)N/A
ROIC(5y)N/A
DYN Yearly ROA, ROE, ROICDYN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

DYN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DYN Yearly Profit, Operating, Gross MarginsDYN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for DYN has been increased compared to 1 year ago.
DYN has more shares outstanding than it did 5 years ago.
There is no outstanding debt for DYN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DYN Yearly Shares OutstandingDYN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
DYN Yearly Total Debt VS Total AssetsDYN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 10.92 indicates that DYN is not in any danger for bankruptcy at the moment.
DYN has a Altman-Z score of 10.92. This is amongst the best in the industry. DYN outperforms 87.99% of its industry peers.
There is no outstanding debt for DYN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.92
ROIC/WACCN/A
WACCN/A
DYN Yearly LT Debt VS Equity VS FCFDYN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

DYN has a Current Ratio of 20.35. This indicates that DYN is financially healthy and has no problem in meeting its short term obligations.
DYN's Current ratio of 20.35 is amongst the best of the industry. DYN outperforms 93.73% of its industry peers.
A Quick Ratio of 20.35 indicates that DYN has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 20.35, DYN belongs to the top of the industry, outperforming 93.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 20.35
Quick Ratio 20.35
DYN Yearly Current Assets VS Current LiabilitesDYN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

DYN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.57%, which is quite good.
EPS 1Y (TTM)9.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, DYN will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.12% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-20.3%
EPS Next 2Y-8.77%
EPS Next 3Y-0.3%
EPS Next 5Y13.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DYN Yearly Revenue VS EstimatesDYN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
DYN Yearly EPS VS EstimatesDYN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DYN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year DYN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DYN Price Earnings VS Forward Price EarningsDYN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DYN Per share dataDYN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.77%
EPS Next 3Y-0.3%

More info and screens

0

5. Dividend

5.1 Amount

DYN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DYNE THERAPEUTICS INC

NASDAQ:DYN (7/14/2025, 12:12:33 PM)

9.01

+0.37 (+4.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)07-31 2025-07-31/amc
Inst Owners105.25%
Inst Owner Change0%
Ins Owners0.27%
Ins Owner Change0.26%
Market Cap1.24B
Analysts82.86
Price Target46.99 (421.53%)
Short Float %19.1%
Short Ratio7.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.46%
Min EPS beat(2)-18.24%
Max EPS beat(2)9.33%
EPS beat(4)2
Avg EPS beat(4)-9.73%
Min EPS beat(4)-33.5%
Max EPS beat(4)9.33%
EPS beat(8)2
Avg EPS beat(8)-13.38%
EPS beat(12)4
Avg EPS beat(12)-9.1%
EPS beat(16)5
Avg EPS beat(16)-7.46%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.12%
PT rev (3m)-8.98%
EPS NQ rev (1m)2.91%
EPS NQ rev (3m)-7.17%
EPS NY rev (1m)-2.73%
EPS NY rev (3m)-10.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.86
P/tB 1.86
EV/EBITDA N/A
EPS(TTM)-3.59
EYN/A
EPS(NY)-3.96
Fwd EYN/A
FCF(TTM)-2.34
FCFYN/A
OCF(TTM)-2.32
OCFYN/A
SpS0
BVpS4.85
TBVpS4.85
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -50.91%
ROE -54.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-81.24%
ROA(5y)-59.12%
ROE(3y)-125.15%
ROE(5y)-86.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 176.97%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20.35
Quick Ratio 20.35
Altman-Z 10.92
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)122.78%
Cap/Depr(5y)173.23%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.63%
EPS Next Y-20.3%
EPS Next 2Y-8.77%
EPS Next 3Y-0.3%
EPS Next 5Y13.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-49.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-30.43%
EBIT Next 3Y-13.51%
EBIT Next 5YN/A
FCF growth 1Y-112.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-113.41%
OCF growth 3YN/A
OCF growth 5YN/A